vs
CoStar Group（CSGP）とEncompass Health Corp（EHC）の財務データ比較。上の社名をクリックして会社を切り替えられます
Encompass Health Corpの直近四半期売上が大きい（$1.5B vs $899.9M、CoStar Groupの約1.7倍）。Encompass Health Corpの純利益率が高く（9.5% vs 5.2%、差は4.3%）。CoStar Groupの前年同期比売上増加率が高い（26.9% vs 9.9%）。Encompass Health Corpの直近四半期フリーキャッシュフローが多い（$116.7M vs $101.3M）。過去8四半期でCoStar Groupの売上複合成長率が高い（17.1% vs 8.3%）
CoStar Groupは1987年に設立された米国の商業不動産向けサービス企業で、本社はバージニア州アーリントンに所在します。北米・欧州を事業エリアとし、商業不動産業界向けの情報、分析、マーケティングサービスを提供するほか、複数のオンラインプラットフォームを運営しています。
エンコンパスヘルスコーポレーション（旧Amcare、HealthSouth）は米国アラバマ州バーミンガムに本社を置く米国最大の入院リハビリサービス事業者で、39州とプエルトリコに173の入院リハビリ病院を展開し、脳卒中や神経疾患、心肺疾患、脳損傷から回復中の患者に専門的な治療とケアを提供している。
CSGP vs EHC — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $899.9M | $1.5B |
| 純利益 | $46.5M | $146.1M |
| 粗利率 | 78.6% | — |
| 営業利益率 | 5.5% | 16.7% |
| 純利益率 | 5.2% | 9.5% |
| 売上前年比 | 26.9% | 9.9% |
| 純利益前年比 | -22.2% | 20.8% |
| EPS（希薄化後） | $0.12 | $1.43 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $899.9M | $1.5B | ||
| Q3 25 | $833.6M | $1.5B | ||
| Q2 25 | $781.3M | $1.5B | ||
| Q1 25 | $732.2M | $1.5B | ||
| Q4 24 | $709.4M | $1.4B | ||
| Q3 24 | $692.6M | $1.4B | ||
| Q2 24 | $677.8M | $1.3B | ||
| Q1 24 | $656.4M | $1.3B |
| Q4 25 | $46.5M | $146.1M | ||
| Q3 25 | $-30.9M | $126.5M | ||
| Q2 25 | $6.2M | $142.1M | ||
| Q1 25 | $-14.8M | $151.5M | ||
| Q4 24 | $59.8M | $120.9M | ||
| Q3 24 | $53.0M | $108.2M | ||
| Q2 24 | $19.2M | $114.1M | ||
| Q1 24 | $6.7M | $112.5M |
| Q4 25 | 78.6% | — | ||
| Q3 25 | 79.3% | — | ||
| Q2 25 | 78.5% | — | ||
| Q1 25 | 79.1% | — | ||
| Q4 24 | 80.1% | — | ||
| Q3 24 | 79.7% | — | ||
| Q2 24 | 80.0% | — | ||
| Q1 24 | 78.5% | — |
| Q4 25 | 5.5% | 16.7% | ||
| Q3 25 | -6.1% | 14.9% | ||
| Q2 25 | -3.5% | 16.2% | ||
| Q1 25 | -5.8% | 16.4% | ||
| Q4 24 | 5.6% | 14.3% | ||
| Q3 24 | 3.4% | 13.6% | ||
| Q2 24 | -2.4% | 14.3% | ||
| Q1 24 | -6.5% | 13.6% |
| Q4 25 | 5.2% | 9.5% | ||
| Q3 25 | -3.7% | 8.6% | ||
| Q2 25 | 0.8% | 9.7% | ||
| Q1 25 | -2.0% | 10.4% | ||
| Q4 24 | 8.4% | 8.6% | ||
| Q3 24 | 7.7% | 8.0% | ||
| Q2 24 | 2.8% | 8.8% | ||
| Q1 24 | 1.0% | 8.5% |
| Q4 25 | $0.12 | $1.43 | ||
| Q3 25 | $-0.07 | $1.24 | ||
| Q2 25 | $0.01 | $1.39 | ||
| Q1 25 | $-0.04 | $1.48 | ||
| Q4 24 | $0.14 | $1.18 | ||
| Q3 24 | $0.13 | $1.06 | ||
| Q2 24 | $0.05 | $1.12 | ||
| Q1 24 | $0.02 | $1.10 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $1.6B | $72.2M |
| 総負債低いほど良い | $140.0M | $2.4B |
| 株主資本純資産 | $8.3B | $2.4B |
| 総資産 | $10.5B | $7.1B |
| 負債/資本比率低いほどレバレッジが低い | 0.02× | 1.00× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $1.6B | $72.2M | ||
| Q3 25 | $1.9B | $48.7M | ||
| Q2 25 | $3.6B | $99.1M | ||
| Q1 25 | $3.7B | $95.8M | ||
| Q4 24 | $4.7B | $85.4M | ||
| Q3 24 | — | $147.8M | ||
| Q2 24 | — | $154.4M | ||
| Q1 24 | — | $134.4M |
| Q4 25 | $140.0M | $2.4B | ||
| Q3 25 | $1.0B | $2.4B | ||
| Q2 25 | $1.0B | $2.3B | ||
| Q1 25 | $1.0B | $2.3B | ||
| Q4 24 | $1.0B | $2.4B | ||
| Q3 24 | $1.0B | $2.3B | ||
| Q2 24 | $1.0B | $2.7B | ||
| Q1 24 | $1.0B | $2.7B |
| Q4 25 | $8.3B | $2.4B | ||
| Q3 25 | $8.6B | $2.4B | ||
| Q2 25 | $8.6B | $2.3B | ||
| Q1 25 | $8.6B | $2.2B | ||
| Q4 24 | $7.6B | $2.1B | ||
| Q3 24 | $7.5B | $2.0B | ||
| Q2 24 | $7.4B | $1.8B | ||
| Q1 24 | $7.3B | $1.7B |
| Q4 25 | $10.5B | $7.1B | ||
| Q3 25 | $10.8B | $6.9B | ||
| Q2 25 | $10.5B | $6.8B | ||
| Q1 25 | $10.4B | $6.6B | ||
| Q4 24 | $9.3B | $6.5B | ||
| Q3 24 | $9.1B | $6.5B | ||
| Q2 24 | $9.1B | $6.4B | ||
| Q1 24 | $9.0B | $6.2B |
| Q4 25 | 0.02× | 1.00× | ||
| Q3 25 | 0.12× | 1.01× | ||
| Q2 25 | 0.12× | 1.02× | ||
| Q1 25 | 0.12× | 1.08× | ||
| Q4 24 | 0.13× | 1.14× | ||
| Q3 24 | 0.13× | 1.20× | ||
| Q2 24 | 0.14× | 1.46× | ||
| Q1 24 | 0.14× | 1.54× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $162.1M | $346.0M |
| フリーキャッシュフロー営業CF - 設備投資 | $101.3M | $116.7M |
| FCFマージンFCF / 売上 | 11.3% | 7.6% |
| 設備投資強度設備投資 / 売上 | 6.8% | 14.8% |
| キャッシュ転換率営業CF / 純利益 | 3.49× | 2.37× |
| 直近12ヶ月FCF直近4四半期 | $123.0M | $439.2M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $162.1M | $346.0M | ||
| Q3 25 | $68.2M | $270.8M | ||
| Q2 25 | $146.5M | $270.2M | ||
| Q1 25 | $53.2M | $288.6M | ||
| Q4 24 | $94.6M | $278.8M | ||
| Q3 24 | $100.3M | $267.8M | ||
| Q2 24 | $58.1M | $217.4M | ||
| Q1 24 | $139.6M | $238.8M |
| Q4 25 | $101.3M | $116.7M | ||
| Q3 25 | $-5.5M | $83.7M | ||
| Q2 25 | $27.7M | $113.3M | ||
| Q1 25 | $-500.0K | $125.5M | ||
| Q4 24 | $25.2M | $80.1M | ||
| Q3 24 | $40.2M | $120.3M | ||
| Q2 24 | $-14.7M | $60.5M | ||
| Q1 24 | $-237.1M | $99.4M |
| Q4 25 | 11.3% | 7.6% | ||
| Q3 25 | -0.7% | 5.7% | ||
| Q2 25 | 3.5% | 7.8% | ||
| Q1 25 | -0.1% | 8.6% | ||
| Q4 24 | 3.6% | 5.7% | ||
| Q3 24 | 5.8% | 8.9% | ||
| Q2 24 | -2.2% | 4.6% | ||
| Q1 24 | -36.1% | 7.6% |
| Q4 25 | 6.8% | 14.8% | ||
| Q3 25 | 8.8% | 12.7% | ||
| Q2 25 | 15.2% | 10.8% | ||
| Q1 25 | 7.3% | 11.2% | ||
| Q4 24 | 9.8% | 14.1% | ||
| Q3 24 | 8.7% | 10.9% | ||
| Q2 24 | 10.7% | 12.1% | ||
| Q1 24 | 57.4% | 10.6% |
| Q4 25 | 3.49× | 2.37× | ||
| Q3 25 | — | 2.14× | ||
| Q2 25 | 23.63× | 1.90× | ||
| Q1 25 | — | 1.90× | ||
| Q4 24 | 1.58× | 2.31× | ||
| Q3 24 | 1.89× | 2.48× | ||
| Q2 24 | 3.03× | 1.91× | ||
| Q1 24 | 20.84× | 2.12× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
CSGP
| Co Star | $503.8M | 56% |
| Other | $283.0M | 31% |
| Loop Net | $94.7M | 11% |
EHC
| Medicare | $1.0B | 66% |
| Medicare Advantage | $243.1M | 16% |
| Managed Care | $160.7M | 10% |
| Medicaid | $47.0M | 3% |
| Other Income Source | $44.8M | 3% |
| Other Thirdparty Payors | $11.2M | 1% |
| Workers Compensation | $7.6M | 0% |
| Patients | $4.6M | 0% |
